Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
PLAINSBORO, N.J., Feb. 28, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conferences in March:
- At 9:00AM ET on Tuesday, March 14, 2017, Mr. Glenn Coleman, Chief Financial Officer and Corporate VP of International, will present at Barclays’ Global Healthcare Conference in Miami, FL. This presentation will be webcast.
- At 9:45AM ET on Tuesday, March 21, 2017, Mr. Coleman will present at Oppenheimer’s 27th Annual Healthcare Conference in New York City. This presentation will be webcast.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]
